| Project/Area Number |
18591491
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Tazuke Kofukai Medical Research Institute |
|---|
Principal Investigator |
HIROKI Hashida Tazuke Kofukai Medical Research Institute, 2 Division, Medical Research Institute, Resrarcher (70281607)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥3,830,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥330,000)
Fiscal Year 2007: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2006: ¥2,400,000 (Direct Cost: ¥2,400,000)
|
|---|
| Keywords | SOX4 / Colon Cancer / Colon Development / Wnt Signaling / Vaccine Therapy |
|---|
| Research Abstract |
Gene expression profiling of embryonic mouse colon development was performed to identify regulated genes whose misexpression might associate with colon cancer Transcription factor SOX4 was identified as the one of top genes whose expression down-regulated as colon undergoes developmental maturation from undifferentiated endoderm to a more differentiated polarized epithelium (embryonic day 13.5-18.5). Its expression was increased in human colon adenomas compared to normal colon mucosa and its expression increased more than that during colon cancer development SOX4 expression was found nucleus and /or cytoplasm in colon cancer cells as various patterns. In human colon cancer cells with APC mutation, endogenous SOX4 and beta-catenin interact, co-localize in nucleus partially.
In the serial analysis of gene expression (SAGE) database, SOX4 expression was increased in colon cancer cell lines and actual colon cancer tissues compared to human normal colon tissues. SOX4 transfectants were produced using HEK293 cells and several colon cancer cell lines (SW480, HT29 etc). The luciferase assay showed that SOX4 transfectants regulated the Wnt signaling to stabilize beta-catenin.
In addition, to examine the potential of SOX4 for broad use as a colon cancer vaccine and the immunological potential, SOX4 specific CD4 and CD8 T cells were evaluated. Our preliminary study demonstrated that the identification of natural processed T cell from SOX4 provided development of peptide-based vaccination therapy for colon cancer.
|
